# US Pemphigus Market

> US Pemphigus Market Research Report By Type (Pemphigus Vulgaris, Pemphigus Foliaceus, Pemphigus Vegetans, Paraneoplastic Pemphigus), By End User (Laboratories, Hospitals and Clinics, Academic and Research Institutes), By Diagnosis (Skin Peeling, Skin Biopsy, Blood Tests, Endoscopy), By Treatment (Initial Therapy, Maintenance Therapy, Immunosuppressants, Biological Therapies, Intravenous Immunoglobulin (IVIG) Therapy, Other Medication), By Region - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.6%
- **2024:** $ 121.57 Million
- **2025:** $ 133.16 Million
- **2035:** $ 272.09 Million
- **Key Players:** Amgen Inc (US), Bristol-Myers Squibb Company (US), Genentech Inc (US), Johnson & Johnson (US), Novartis Pharmaceuticals Corporation (US), Pfizer Inc (US), Roche Holding AG (US), Sanofi (US), AbbVie Inc (US)

**Report ID:** MRFR/Pharma/17389-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-pemphigus-market-18935

---

## Market Summary

## US Pemphigus Market Highlighted Trends & Dynamics

The US Pemphigus market is a vital component of the healthcare sector, focusing on addressing the challenges posed by a rare autoimmune blistering disorder known as pemphigus. This condition primarily affects the skin and mucous membranes, leading to the formation of painful blisters and erosions. Pemphigus is characterized by an immune system malfunction that targets the proteins within the skin and mucous membranes, causing them to separate. The demand for effective treatments within the US Pemphigus market is driven by the need to alleviate symptoms, prevent complications, and improve the quality of life for individuals grappling with this autoimmune disorder.

One of the key factors influencing the demand for pemphigus treatments in the US market is the rarity and complexity of the condition. Pemphigus is considered a rare disease, and its autoimmune nature presents challenges in both diagnosis and management. As awareness of pemphigus increases among healthcare professionals, there is a growing emphasis on the development of targeted therapies and multidisciplinary approaches to address the specific immunological mechanisms underlying the disorder. The market responds by providing a range of therapeutic options, including immunosuppressive medications, corticosteroids, and emerging biologic agents that target specific components of the immune response.

Advancements in medical research contribute significantly to shaping the landscape of the US Pemphigus market. As understanding of the immunological processes involved in pemphigus deepens, there is an increasing focus on developing more targeted and effective treatments. Biologics, such as rituximab, have emerged as promising options, offering a more precise approach to modulating the immune response. Research efforts also explore the genetic and molecular basis of pemphigus, providing insights into potential biomarkers and therapeutic targets that can further enhance the development of novel treatments within the market.

The demand within the US Pemphigus market is further driven by the need for comprehensive and personalized care. Pemphigus manifests in various forms, including pemphigus vulgaris and pemphigus foliaceus, each requiring a tailored approach to treatment. The market acknowledges the importance of individualized care plans that consider the severity of symptoms, the patient's overall health, and potential side effects of medications. This patient-centric approach aligns with the broader trend in healthcare toward precision medicine, recognizing the unique characteristics of each patient's condition and optimizing treatment outcomes.

Moreover, the market dynamics are influenced by the challenges associated with the long-term management of pemphigus. The chronic nature of the disorder necessitates ongoing treatment to control symptoms and prevent relapses. However, the use of immunosuppressive medications, which is common in pemphigus management, poses potential risks and side effects. The market responds by emphasizing close monitoring, regular follow-up appointments, and a collaborative approach between healthcare providers and patients to ensure optimal treatment outcomes while minimizing adverse effects.

Patient advocacy and awareness initiatives play a crucial role in shaping the US Pemphigus market. Organizations dedicated to pemphigus education and support contribute to increased awareness among both healthcare professionals and the general public. By providing resources, facilitating communication, and fostering a sense of community, these advocacy efforts contribute to early diagnosis, improved access to treatments, and a better understanding of the challenges faced by individuals with pemphigus.

Additionally, the market dynamics are influenced by healthcare policies, insurance coverage, and reimbursement considerations. Ensuring access to innovative and potentially costly treatments is essential for individuals with pemphigus. Efforts to advocate for favorable reimbursement policies and increased insurance coverage for pemphigus treatments contribute to the accessibility of advanced therapies within the market, addressing the financial barriers that patients may encounter.

## Market Drivers

### Increased Research Funding

The US Pemphigus Market benefits from increased research funding aimed at understanding and treating pemphigus. Government agencies, such as the National Institutes of Health (NIH), have allocated substantial resources to research initiatives focused on autoimmune diseases, including pemphigus. This funding supports clinical trials, basic research, and the development of new therapeutic approaches. The growing interest in pemphigus research is reflected in the rising number of publications and clinical studies, which enhance the understanding of disease mechanisms and potential treatment targets. As research progresses, it is anticipated that new therapies will emerge, further driving the US Pemphigus Market. The collaboration between academic institutions and pharmaceutical companies is also likely to foster innovation, leading to the development of novel treatment options that address unmet medical needs in the pemphigus patient population.

### Rising Incidence of Pemphigus

The US Pemphigus Market is experiencing a notable increase in the incidence of pemphigus, a rare autoimmune blistering disorder. Recent data suggests that the prevalence of pemphigus vulgaris and pemphigus foliaceus is on the rise, with estimates indicating that approximately 0.5 to 3 cases per 100,000 individuals are diagnosed annually in the United States. This growing patient population necessitates enhanced treatment options and healthcare resources, thereby driving market growth. Furthermore, the increasing awareness among healthcare professionals regarding the symptoms and complications associated with pemphigus contributes to earlier diagnosis and intervention, which is crucial for improving patient outcomes. As the number of diagnosed cases continues to grow, the US Pemphigus Market is likely to expand, attracting pharmaceutical companies to invest in research and development of innovative therapies.

### Advancements in Biologic Therapies

The US Pemphigus Market is significantly influenced by advancements in biologic therapies, which have revolutionized the treatment landscape for autoimmune diseases. Biologics, such as monoclonal antibodies, target specific pathways involved in the pathogenesis of pemphigus, offering more effective and personalized treatment options. The introduction of therapies like rituximab has shown promising results in clinical trials, leading to increased adoption among healthcare providers. Market data indicates that the biologics segment is projected to grow at a compound annual growth rate (CAGR) of over 10% in the coming years. This growth is driven by the need for more effective treatments that minimize side effects compared to traditional corticosteroids. As the US Pemphigus Market continues to embrace these innovative therapies, patient outcomes are expected to improve, further stimulating market expansion.

### Regulatory Support for New Treatments

The US Pemphigus Market is positively impacted by regulatory support for the approval of new treatments. The Food and Drug Administration (FDA) has implemented expedited review processes for therapies targeting rare diseases, including pemphigus. This regulatory framework encourages pharmaceutical companies to invest in the development of innovative treatments, as it reduces the time and cost associated with bringing new drugs to market. The recent approval of therapies specifically designed for pemphigus has demonstrated the FDA's commitment to addressing the needs of patients with this rare condition. As more treatments receive regulatory approval, the US Pemphigus Market is expected to grow, providing patients with access to a wider array of therapeutic options. This supportive regulatory environment fosters competition among manufacturers, which may lead to improved treatment outcomes and lower costs for patients.

### Growing Awareness and Education Initiatives

The US Pemphigus Market is experiencing growth due to increasing awareness and education initiatives aimed at both healthcare professionals and patients. Organizations dedicated to pemphigus advocacy are actively working to disseminate information about the disease, its symptoms, and available treatment options. This heightened awareness is crucial for early diagnosis and effective management of pemphigus, as many patients remain undiagnosed or misdiagnosed. Educational programs and workshops for healthcare providers are being implemented to enhance their understanding of pemphigus and its treatment protocols. As awareness increases, more patients are likely to seek medical attention, leading to a rise in diagnosed cases and, consequently, a growing demand for therapies. The US Pemphigus Market stands to benefit from these initiatives, as they contribute to improved patient outcomes and a more informed healthcare landscape.

## Future Outlook

The US Pemphigus Market is projected to grow at a 7.6% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing awareness, and rising healthcare expenditure.

**New opportunities:**

- Development of targeted biologic therapies for Pemphigus patients.
- Expansion of telehealth services for remote patient monitoring.
- Investment in patient education programs to enhance treatment adherence.

By 2035, the Pemphigus Market is expected to achieve substantial growth, reflecting evolving treatment paradigms.

## Segment Insights

### By Type: Pemphigus Vulgaris (Largest) vs. Pemphigus Foliaceus (Fastest-Growing)

In the US pemphigus market, Pemphigus Vulgaris holds the largest share due to its prevalence and more severe manifestations compared to other types. Pemphigus Foliaceus, while smaller in market share, is the fastest-growing segment due to increasing recognition and diagnosis, coupled with expanding treatment options tailored for less severe skin involvement. 

Growth trends in this segment are being driven by advancements in targeted therapies and biologics that address the underlying mechanisms of the disease. The increased awareness of autoimmune conditions among healthcare providers and the rise in research initiatives are contributing to the adoption of effective treatment protocols. Additionally, the aging population is a significant factor, as pemphigus diseases are more common in older adults, further boosting market dynamics.

Pemphigus Vulgaris (Dominant) vs. Pemphigus Foliaceus (Emerging)

Pemphigus Vulgaris remains the dominant segment in the US pemphigus market due to its clinical severity and the urgency of treatment required. It is characterized by painful blisters and erosions on the skin and mucous membranes, necessitating robust therapeutic interventions. In contrast, Pemphigus Foliaceus is emerging rapidly, presenting milder symptoms primarily affecting the skin. This segment has garnered attention due to its growing treatment avenues, including topical therapies and systemic medications that specifically target its less aggressive nature. Both segments reflect the ongoing evolution in understanding and managing pemphigus conditions, aligning treatment strategies with specific clinical profiles. The coexistence of these segments illustrates a significant shift in therapeutic approaches and patient management.

### By Diagnosis: Skin Biopsy (Largest) vs. Blood Tests (Fastest-Growing)

In the US pemphigus market, the Diagnosis segment showcases a diverse array of methodologies. Among these, Skin Biopsy holds the largest market share, being the most reliable and widely accepted method for diagnosing pemphigus, contributing significantly to overall market dynamics. Blood Tests, while not as dominant, are rapidly gaining traction due to advancements in technology and the increasing prevalence of pemphigus, indicating a shift towards more efficient and patient-friendly diagnostic alternatives.

The growth trends within the Diagnosis segment are influenced by various factors including technological advancements, rising awareness, and the increasing incidence of pemphigus. Innovations in diagnostic tools such as non-invasive Blood Tests are encouraging a more comprehensive approach to early diagnosis. Additionally, the integration of digital health solutions is streamlining workflows and improving access, ultimately enhancing patient outcomes and driving the growth of newer diagnostic methodologies in the US pemphigus market.

Skin Biopsy (Dominant) vs. Blood Tests (Emerging)

Skin Biopsy remains the dominant force in the Diagnosis segment due to its established reliability and accuracy in detecting pemphigus. This method entails the surgical removal of a small section of skin for analysis, providing definitive results that help healthcare providers make informed decisions. Conversely, Blood Tests are emerging as a popular alternative, primarily because they offer a less invasive approach with quicker results. As advancements continue in the realm of serological tests, Blood Tests are becoming an attractive choice for both patients and healthcare providers, marking their transition into a key player within the market.

### By Treatment: Biological Therapies (Largest) vs. Immunosuppressants (Fastest-Growing)

In the US pemphigus market, Biological Therapies emerge as the largest segment, capturing a significant share due to their efficacy in managing severe cases. In contrast, Immunosuppressants are gaining traction and are recognized as the fastest-growing segment due to their increasing adoption in treating various autoimmune conditions, including pemphigus.

The growth trends in the treatment segment are fueled by ongoing research and development into more effective therapies. The rise of [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) and advancements in biological therapies contribute to the robust market dynamics. Adoption of Immunosuppressants continues to accelerate, particularly as healthcare providers seek cost-effective solutions, leading to a competitive landscape characterized by innovation and improved patient outcomes.

Biological Therapies (Dominant) vs. Immunosuppressants (Emerging)

Biological Therapies, as the dominant force in treatment options, offer targeted mechanisms that address the underlying causes of pemphigus, providing relief to patients with refractory cases. These therapies are increasingly preferred due to their strong clinical evidence supporting efficacy and safety. Conversely, Immunosuppressants represent an emerging solution in this segment, expanding their utilization as they prove effective in stabilizing disease manifestations. Innovations in this category continue to refine treatment approaches, enhancing the quality of life for patients. Manufacturers are focusing on optimizing these therapies to mitigate side effects, driving their adoption in clinical settings, and thus shaping the future of pemphigus management.

### By End User: Hospitals and Clinics (Largest) vs. Laboratories (Fastest-Growing)

In the US pemphigus market, the segment distribution reveals that Hospitals and Clinics hold the largest share, reflecting their crucial role in managing patient care and treatment. Meanwhile, Laboratories are emerging rapidly and gaining market traction, driven by innovations in diagnostic techniques and the growing focus on personalized medicine. This dynamic landscape showcases the importance of both segments in addressing the needs of pemphigus patients and their treatment paradigms.

Growth trends in the US pemphigus market indicate a significant increase in the demand for services from Hospitals and Clinics, attributed to rising patient awareness and the adoption of advanced treatment protocols. Conversely, Laboratories are witnessing rapid expansion, fueled by technological advancements and an increasing emphasis on research and development. These trends highlight a collaborative ecosystem where both segments enhance the overall patient experience and treatment outcomes.

Hospitals and Clinics (Dominant) vs. Laboratories (Emerging)

Hospitals and Clinics serve as the dominant players in the US pemphigus market, providing comprehensive care and treatment options for patients. Their established presence and ability to offer multidisciplinary care make them vital in the management of pemphigus. On the other hand, Laboratories are becoming increasingly important in this market as emerging players, driven by their innovative diagnostic capabilities and contribution to research. The evolution of advanced testing methodologies has enabled Laboratories to support clinical decision-making effectively. Together, these segments create a robust framework for ensuring effective treatment strategies and improving overall patient outcomes in the US pemphigus market.

## Competitive Benchmarking

The Pemphigus Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Amgen Inc (US), Bristol-Myers Squibb Company (US), and AbbVie Inc (US) are actively engaged in developing novel therapies and expanding their market presence. Amgen Inc (US) has positioned itself as a leader in biologics, emphasizing research and development to enhance treatment efficacy. Meanwhile, Bristol-Myers Squibb Company (US) has been focusing on strategic acquisitions to bolster its portfolio, particularly in immunology, which is crucial for addressing autoimmune diseases like pemphigus. AbbVie Inc (US) is also notable for its commitment to innovation, particularly through its robust pipeline of monoclonal antibodies aimed at treating various forms of pemphigus, thereby shaping the competitive dynamics of the market.

The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The Pemphigus Market appears to be moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they leverage their resources to enhance distribution networks and improve access to therapies. This competitive structure fosters an environment where innovation is paramount, and companies are incentivized to differentiate their offerings through advanced research and development.

In December 2025, Amgen Inc (US) announced a collaboration with a leading research institution to explore novel therapeutic targets for pemphigus. This strategic move is likely to enhance Amgen's research capabilities and accelerate the development of new treatment options, positioning the company favorably in a competitive market. Similarly, in November 2025, AbbVie Inc (US) received FDA approval for a new indication of its monoclonal antibody, which is expected to significantly expand its market share and reinforce its commitment to addressing unmet medical needs in pemphigus patients. This approval not only underscores AbbVie's innovative approach but also highlights the importance of regulatory milestones in shaping competitive positioning.

In October 2025, Bristol-Myers Squibb Company (US) launched a new patient support program aimed at improving treatment adherence among pemphigus patients. This initiative reflects a growing trend among pharmaceutical companies to enhance patient engagement and support, which is increasingly recognized as a critical component of successful treatment outcomes. By investing in patient-centric strategies, Bristol-Myers Squibb is likely to strengthen its brand loyalty and improve its competitive standing in the market.

As of January 2026, the Pemphigus Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in [drug development](https://www.marketresearchfuture.com/reports/drug-development-market-66529). Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in accelerating innovation and improving patient outcomes. The competitive landscape is shifting from traditional price-based competition to a focus on technological advancements and supply chain reliability. This evolution suggests that companies that prioritize innovation and patient-centric solutions will likely emerge as leaders in the Pemphigus Market.

## Report Scope

| MARKET SIZE 2024 | 121.57(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 133.16(USD Million) |
| MARKET SIZE 2035 | 272.09(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.6% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Amgen Inc (US), Bristol-Myers Squibb Company (US), Genentech Inc (US), Johnson & Johnson (US), Novartis Pharmaceuticals Corporation (US), Pfizer Inc (US), Roche Holding AG (US), Sanofi (US), AbbVie Inc (US) |
| Segments Covered | Disease Type, Treatment Type, Patient Demographics, Route of Administration |
| Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the US Pemphigus Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the US Pemphigus Market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US pemphigus market in 2024?**
A: The overall market valuation was $121.57 Million in 2024.

**Q: What is the projected market valuation for the US pemphigus market by 2035?**
A: The projected valuation for 2035 is $296.18 Million.

**Q: What is the expected CAGR for the US pemphigus market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 8.43%.

**Q: Which companies are considered key players in the US pemphigus market?**
A: Key players include Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Amgen (US), Sanofi (FR), Merck & Co (US), Pfizer (US), and GSK (GB).

**Q: What are the market segments for the US pemphigus market?**
A: Market segments include Type, Diagnosis, Treatment, and End User.

**Q: What was the valuation for Pemphigus Vulgaris in 2024?**
A: The valuation for Pemphigus Vulgaris was $60.79 Million in 2024.

**Q: How much is the Blood Tests segment projected to be valued by 2035?**
A: The Blood Tests segment is projected to be valued at $80.0 Million by 2035.

**Q: What is the projected valuation for Immunosuppressants in 2035?**
A: The projected valuation for Immunosuppressants is $80.0 Million by 2035.

**Q: What was the valuation for Hospitals and Clinics in 2024?**
A: The valuation for Hospitals and Clinics was $60.79 Million in 2024.

**Q: What is the expected growth trend for the US pemphigus market in the coming years?**
A: The US pemphigus market is expected to grow steadily, reaching $296.18 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-pemphigus-market-18935*